ADMA Biologics

YTD

ALL

Trade ADMA Biologics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ADMA

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center.

CEO

Adam S. Grossman

CEOAdam S. Grossman

Employees

647

Employees647

Headquarters

Ramsey, New Jersey

HeadquartersRamsey, New Jersey

Founded

2004

Founded2004

Employees

647

Employees647

ADMA Key Statistics

Market cap

1.99B

Market cap1.99B

Price-Earnings ratio

12.54

Price-Earnings ratio12.54

Dividend yield

—

Dividend yield—

Average volume

3.30M

Average volume3.30M

High today

$8.80

High today$8.80

Low today

$8.41

Low today$8.41

Open price

$8.43

Open price$8.43

Volume

3.40M

Volume3.40M

52 Week high

$20.46

52 Week high$20.46

52 Week low

$7.21

52 Week low$7.21

Stock Snapshot

With a market cap of 1.99B, ADMA Biologics(ADMA) trades at $8.53. The stock has a price-to-earnings ratio of 12.54.

During the trading session on 2026-06-17, ADMA Biologics(ADMA) shares reached a daily high of $8.80 and a low of $8.41. At a current price of $8.53, the stock is +1.4% higher than the low and still -3.1% under the high.

Trading volume for ADMA Biologics(ADMA) stock has reached 3.4M, versus its average volume of 3.3M.

Over the past 52 weeks, ADMA Biologics(ADMA) stock has traded between a high of $20.46 and a low of $7.21.

ADMA News

TipRanks 2d

ADMA Biologics Faces Federal Securities Lawsuit Over Alleged Channel Stuffing Scheme and Undisclosed Related Party Transactions

ADMA Biologics, Inc. (NASDAQ: ADMA) is facing a federal securities lawsuit after a short seller report and subsequent disclosures allegedly revealed that the co...

Barchart 2d

Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Barchart.com

...

TipRanks 2d

ADMA: Buy Rating Reiterated on Strong IG Product Momentum, Conservative Expectations and Unchanged $18 Price Target

ADMA Biologics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Gary Nachman from Canaccord Genuity maintained a Buy ra...

More ADMA News

Simply Wall St 6d

Why ADMA Biologics Is Up 9.3% After Securities Fraud Class Actions Over ASCENIV Sales Practices

In recent months, multiple law firms have filed securities class action lawsuits against ADMA Biologics alleging channel stuffing, misstated revenues, and undis...

TipRanks 7d

Adma Biologics resumed with an Outperform at Raymond James

Raymond James analyst Ryan Deschner resumed coverage of Adma Biologics (ADMA) with an Outperform rating and $21 price target Adma has transformed into a profita...

People also own

Based on the portfolios of people who own ADMA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.